AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A composition comprising (A) a T lymphocyte having (i) a recombinant chimeric receptor, which is reactive with a tumor antigen, and (ii) an endogenous T-cell receptor reactive with a cell that is allogeneic to the T lymphocyte, and (B) the cell that is allogeneic to the T lymphocyte.

2. Cancelled.

3. Cancelled.

4. (Previously Presented) The composition of claim 1, wherein the tumor antigen is an ovarian tumor antigen.

5. Cancelled.

6. Cancelled.

7. (Previously Presented) The composition of claim 1, wherein the chimeric receptor comprises a single chain Fv receptor.

8. (Previously Presented) The composition of claim 1, wherein the cell is a peripheral blood mononuclear cell.

9. Cancelled.

10. (Previously Presented) The composition of claim 4, wherein the recombinant chimeric receptor is Mov-γ.

11. - 39. Cancelled.

40. (Currently Amended) A pharmaceutical composition comprising:

(A) a T lymphocyte containing a recombinant chimeric receptor reactive with a tumor antigen and an endogenous T-cell receptor reactive with a cell that is allogeneic to the T lymphocyte;

(B) the cell that is allogeneic to the T lymphocyte; and

(C) a pharmaceutically acceptable carrier.

41. (Previously Presented) A method of preparing lymphocytes having dual specificity comprising:

contacting lymphocytes with a cell that is allogeneic to the lymphocytes; and

transducing the lymphocytes with a chimeric receptor gene, said gene encoding a chimeric receptor, which is reactive with a tumor antigen.

42. Cancelled.

43. Cancelled.

44. (Previously Presented) The composition of claim 4, wherein the ovarian tumor antigen is folate binding protein (FBP).

45. (Previously Presented) The composition of claim 1, wherein the T lymphocyte is a human T lymphocyte.

46. (Previously Presented) The composition of claim 1, wherein the cell is a splenocyte, a dendritic cell, or a B cell.

47. – 51. Cancelled.

52. (Previously Presented) The pharmaceutical composition of claim 40, wherein the T lymphocyte is a human T lymphocyte.

53. (Previously Presented) The pharmaceutical composition of claim 40, wherein the chimeric receptor is Mov-γ.

54. (Previously Presented) The pharmaceutical composition of claim 40, wherein the tumor antigen is an ovarian tumor antigen.

55. (Previously Presented) The pharmaceutical composition of claim 53, wherein the ovarian tumor antigen is FBP.

56. (Previously Presented) The pharmaceutical composition of claim 40, wherein the cell is a peripheral blood monuclear cell, a splenocyte, a dendritic cell, or a B cell.

57. (Previously Presented) The method of claim 41, wherein the chimeric receptor is Mov-γ.

58. (Previously Presented) The method of claim 41, wherein the cell is a peripheral blood mononuclear cell, a splenocyte, a dendritic cell, or a B cell.

59. (Previously Presented) The method of claim 41, wherein the tumor antigen is an ovarian tumor antigen.

60. (Previously Presented) The method of claim 59, wherein the ovarian tumor antigen is FBP.

61. (Previously Presented) The method of claim 41, wherein the lymphocytes are human lymphocytes.

62. – 70. Cancelled.

71. (Currently Amended) A composition comprising the ~~The~~ lymphocytes prepared by the method of claim 41 and the cell that is allogeneic to the lymphocytes.

72. (Currently Amended) A composition comprising (A) a T lymphocyte having (i) a recombinant T-cell receptor, which is reactive with a tumor antigen, and (ii) an endogenous T-cell receptor reactive with a cell that is allogeneic to the T lymphocyte and (B) the cell that is allogeneic to the T lymphocyte.

73. (Previously Presented) The composition of claim 72, wherein the tumor antigen is an ovarian tumor antigen.

74. (Previously Presented) The composition of claim 73, wherein the ovarian tumor antigen is folate binding protein (FBP).

75. (Previously Presented) The composition of claim 72, wherein the cell is a peripheral blood mononuclear cell, splenocyte, a dendritic cell, or a B cell.

76. (Previously Presented) The composition of claim 72, wherein the T lymphocyte is a human T lymphocyte.

77. Cancelled.

78. Cancelled.

79. (Currently Amended) A composition comprising a population of T lymphocytes comprising

(a) a recombinant chimeric receptor that is reactive with a tumor antigen, and

(b) a T-cell receptor that is reactive with an allogeneic cell,

wherein the population of ~~T-cells~~ T lymphocytes has been exposed to a cell that is allogeneic to ~~at least one of the~~ an individual or subpopulation of T lymphocytes of the population under conditions which expand and activate the individual or subpopulation of T lymphocytes.

80. (Currently Amended) ~~A~~ The composition ~~comprising a population of T lymphocytes~~ of claim 79, wherein the population ~~substantially~~ consists essentially of ~~T-cells~~ T lymphocytes reactive with the ~~allogeneic~~ cell that is allogeneic to the T lymphocytes.

81. (Currently Amended) A composition comprising a population of T lymphocytes comprising

(a) a recombinant T-cell receptor, which is reactive with a tumor antigen, and

(b) a T-cell receptor that is reactive with an allogeneic cell,

wherein the population of ~~T-cells~~ T lymphocytes has been exposed to a cell that is allogeneic to ~~at least one of the~~ an individual or subpopulation of T lymphocytes of the population under conditions which expand and activate the individual or subpopulation of T lymphocytes.

82. (Currently Amended) ~~A~~ The composition ~~comprising a population of T lymphocytes~~ of claim 81, wherein the population ~~substantially~~ consists essentially of ~~T-cells~~ T lymphocytes reactive with the ~~allogeneic~~ cell that is allogeneic to the T lymphocytes.

83. (New) The method of claim 41 further comprising contacting the lymphocytes with the cell that is allogeneic to the lymphocytes after transducing the lymphocytes with a chimeric receptor gene.

84. (New) The composition of claim 79, wherein the tumor antigen is an ovarian tumor antigen.

85. (New) The composition of claim 84, wherein the ovarian tumor antigen is folate binding protein (FBP).

86. (New) The composition of claim 79, wherein the cell is a peripheral blood mononuclear cell, splenocyte, a dendritic cell, or a B cell.

87. (New) The composition of claim 79, wherein the T lymphocyte is a human T lymphocyte.

88. (New) The composition of claim 81, wherein the tumor antigen is an ovarian tumor antigen.

89. (New) The composition of claim 88, wherein the ovarian tumor antigen is folate binding protein (FBP).

90. (New) The composition of claim 81, wherein the cell is a peripheral blood mononuclear cell, splenocyte, a dendritic cell, or a B cell.

91. (New) The composition of claim 81, wherein the T lymphocyte is a human T lymphocyte.

92. (New) The composition of claim 79, wherein the population consists essentially of (i) T lymphocytes reactive with the cell that is allogeneic to the T lymphocytes and (ii) the cell that is allogeneic to the T lymphocytes.

93. (New) The composition of claim 81, wherein the population consists essentially of (i) T lymphocytes reactive with the cell that is allogeneic to the T lymphocytes and (ii) the cell that is allogeneic to the T lymphocytes.